Skip to main content
SpringerLink
Log in

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

In 2003, the uricosuric drug benzbromarone was withdrawn from the market. The first alternative drug of choice was the xanthine oxidase inhibitor allopurinol. The purpose was to (1) investigate the efficacy of allopurinol (standard dosage) compared with previous treatment with benzbromarone; and (2) investigate the combination therapy allopurinol–probenecid as an effective alternative treatment compared with previous benzbromarone treatment. A prospective, open study was carried out in a cohort of 51 gout patients who discontinued benzbromarone therapy because of market withdrawal. Patients were given 200–300 mg allopurinol (stage 1). When allopurinol failed to attain the target serum urate (sUr) levels ≤0.30 mmol/l, probenecid 1,000 mg/day was added (stage 2). Treatment with benzbromarone monotherapy (range: 100–200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr ≤ 0.30 mmol/l with a decrease of 61[11]% compared to baseline. In stage 1, 32 patients completed treatment with allopurinol monotherapy (range 200–300 mg/day; mean 256 mg/day), which resulted in 25% of patients attaining sUr target levels. Decrease in sUr levels was 36[11]%, which was significantly less compared to treatment with benzbromarone (p < 0.001). In stage 2, 14 patients received allopurinol–probenecid combination therapy, which resulted in 86% of patients attaining target sUr levels (after failure on allopurinol monotherapy), which was comparable to previous treatment with benzbromarone (p = 0.81). Decrease in sUr levels was 53[9]% (CI 95%: 48–58%), which was a non-significant difference compared to previous treatment with benzbromarone (p = 0.23). Benzbromarone is a very effective antihyperuricemic drug with 91% success in attainment of target sUr levels ≤0.30 mmol/l. Allopurinol 200–300 mg/day was shown to be a less potent alternative for most selected patients to attain target sUr levels (13% success). In patients failing on allopurinol monotherapy, the addition of probenecid proves to be an effective treatment strategy for attaining sUr target levels (86% success).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jansen TL, Reinders MK, van Roon EN et al (2004) Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 22:651

    PubMed  Google Scholar 

  2. Van der Klauw MM, Houtman PM, Stricker BH et al (1994) Hepatic injury caused by benzbromarone. J Hepatol 20:376–379

    PubMed  Google Scholar 

  3. Wagayama H, Shiraki K, Sugimoto K et al (2000) Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 32:874

    Article  PubMed  CAS  Google Scholar 

  4. Arai M, Yokosuka O, Fujiwara K et al (2002) Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 17:625–626

    Article  PubMed  Google Scholar 

  5. Masbernard A, Giudicelli CP (1981) Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 59:701–706

    PubMed  CAS  Google Scholar 

  6. Sutaria S, Katbamna R, Underwood M (2006) Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review. Rheumatology 45:1422–1431

    Article  PubMed  CAS  Google Scholar 

  7. Choi KH, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143:499–516

    PubMed  CAS  Google Scholar 

  8. Terkeltaub RA (2003) Gout. N Engl Med J 349:1647–1655

    Article  CAS  Google Scholar 

  9. Rott KT, Agudelo CA (2003) Gout. JAMA 289:2857–2860

    Article  PubMed  Google Scholar 

  10. Wortmann RL (2005) Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 17:319–324

    Article  PubMed  CAS  Google Scholar 

  11. Li-Yu J, Clayburne G, Sieck M et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577–580

    PubMed  CAS  Google Scholar 

  12. Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321–325

    Article  PubMed  CAS  Google Scholar 

  13. Yamanaka H, Togashi R, Hakoda M et al (1998) Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 431:13–18

    PubMed  CAS  Google Scholar 

  14. Perez-Ruiz F, Calabozo M, Pijoan JI et al (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47:356–360

    Article  PubMed  CAS  Google Scholar 

  15. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545–549

    Article  PubMed  CAS  Google Scholar 

  16. Hanvivadhanakul P, Akkasilpa S, Deesomchok U (2002) Efficacy of benzbromarone compared to allopurinol in lowering serum urate level in hyperuricemic patients. J Med Assoc Thai 85:S40–S47

    PubMed  Google Scholar 

  17. Pascual E, Batlle-Gualda E, Martinez A et al (1999) Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 131:756–759

    PubMed  CAS  Google Scholar 

  18. Wallace SL, Robinson H, Masi AT et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900

    Article  PubMed  CAS  Google Scholar 

  19. Traynor J, Mactier R, Geddes CC et al (2006) How to measure renal function in clinical practice. BMJ 333:733–737

    Article  PubMed  Google Scholar 

  20. Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:A0828

    Google Scholar 

  21. Kaehny WD, Tangel DJ, Johnson AM et al (1990) Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med 89:49–52

    Article  PubMed  CAS  Google Scholar 

  22. Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56

    Article  PubMed  CAS  Google Scholar 

  23. Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461

    Article  PubMed  CAS  Google Scholar 

  24. Sarawate CA, Patel PA, Schumacher HR et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12:61–65

    Article  PubMed  Google Scholar 

  25. Perez-Ruiz F, Calabozo M, Erauskin GG et al (2002) Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 47:610–613

    Article  PubMed  CAS  Google Scholar 

  26. Yamamoto T, Moriwaki Y, Takahashi S et al (1991) Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 50:631–633

    Article  PubMed  CAS  Google Scholar 

  27. Schlesinger N (2004) Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64:2399–2416

    Article  PubMed  CAS  Google Scholar 

  28. Takahashi S, Moriwaki Y, Yamamoto T et al (2003) Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on urate metabolism. Ann Rheum Dis 62:572–575

    Article  PubMed  CAS  Google Scholar 

  29. Vogt B (2005) Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 20:431–433

    Article  PubMed  CAS  Google Scholar 

  30. Moolenburgh JD, Reinders MK, Jansen TL (2006) Rasburicase treatment in severe tophaceous gout; a novel therapeutic option. Clin Rheumatol 25:749–752

    Article  PubMed  CAS  Google Scholar 

  31. Fam AG (2001) Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 3:29–35

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors thank E.N. Griep, MD, Ph.D. and J.P.L. Spoorenberg, MD, Ph.D. (Medical Centre Leeuwarden) for inclusion of their patients in the study. This work has not been supported by any grant either from the pharmaceutical industry, private or public institutions.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands

    Mattheus K. Reinders, Eric N. van Roon & Jacobus R. B. J. Brouwers

  2. Department of Pharmacotherapy and Pharmaceutical Care, Groningen Research Institute for Pharmacy, University of Groningen, Groningen, The Netherlands

    Mattheus K. Reinders, Eric N. van Roon & Jacobus R. B. J. Brouwers

  3. Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

    Pieternella M. Houtman & Tim L. Th. A. Jansen

Authors
  1. Mattheus K. Reinders
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric N. van Roon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pieternella M. Houtman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacobus R. B. J. Brouwers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim L. Th. A. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mattheus K. Reinders.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinders, M.K., van Roon, E.N., Houtman, P.M. et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26, 1459–1465 (2007). https://doi.org/10.1007/s10067-006-0528-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0528-3

Keywords

Search

Navigation